Person: OGUN, HAMZA
7 results
Search Results
Now showing 1 - 7 of 7
Publication Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators(2024-01-01) Nayır Büyükşahin H.; EMİRALİOĞLU ORDUKAYA N.; Yalçın E.; Şen V.; Selimoğlu Şen H.; Arslan H.; Başkan A. K.; Çakır F. B.; Koray C. F.; Yılmaz A. İ.; et al.; ÇAKIR, FATMA BETÜL; OGUN, HAMZA; YAZAN, HAKAN; ÇAKIR, ERKANIntroduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the ‘Vertex treatment-Finder\" on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p =.010), lower median height z-scores (−0.87 vs. −0.55, p <.001), lower median body mass index z-scores (−0.65 vs. −0.50, p <.001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0–2] vs. 0 [IQR: 0–7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes.Publication Research Burden of Interstitial Lung Diseases in Turkey - RBILD(2022-01-01T00:00:00Z) AYÇİÇEK, OLCAY; Cetinkaya, Erdogan; Ucsular, Fatma Demirci; BAYRAM, NAZAN; Senyigit, Abdurrahman; Aksel, Nimet; ATİLLA, NURHAN; Sarioglu, Nurhan; Niksarlioglu, Elif Yelda; Ilgazli, Ahmet; KILIÇ, TALAT; Günbatar, Hülya; Cilekar, Sule; EKİCİ, AYDANUR; Arinc, Sibel; Bircan, Haci Ahmet; Duman, Dildar; Dikis, Ozlem Sengoren; YAZICI, ONUR; Kansu, Abdulla; TUTAR, NURİ; Ozsari, Emine; BERK, SERDAR; Varol, Yelda; Erbaycu, Ahmet Emin; SERTOĞULLARINDAN, BÜNYAMİN; Cirak, Ali Kadri; Cortuk, Mustafa; Karadeniz, Gulistan; Simsek, Alper; SEZGİ, CENGİZHAN; EREL, FUAT; Ciftci, Tuba; Sünnetçioğlu, Aysel; EKİCİ, MEHMET SAVAŞ; Agca, Meltem; Ozturk, Onder; OGUN, HAMZA; Acar, Elif; Alizoroglu, Dursun; Gezer, Esma; ÖZLÜ, TEVFİK; BİRCAN, HACI AHMET; OGUN, HAMZAIntroduction: The aim of our study is to investigate the etiological distribution of ILD in Turkey by stratifying the epidemiological characteristics of ILD cases, and the direct cost of initial diagnosis of the diag-nosed patients. Material-Method: The study was conducted as a multicenter, prospective, cross-sectional, clinical observation study. Patients over the age of 18 and who accepted to participate to the study were included and evaluated as considered to be ILD. The findings of diagnosis, examination and treatment carried out by the cent-ers in accordance with routine diagnostic procedures were recorded observationally. Results: In total,1070 patients were included in this study. 567 (53%) of the patients were male and 503 (47%) were female. The most frequently diagnosed disease was IPF (30.5%). Dyspnea (75.9%) was the highest incidence among the presenting symptoms. Physical examination found bibasilar inspiratory crackles in 56.2 % and radiological findings included reticular opacities and interlobular septal thickenings in 55.9 % of the cases. It was observed that clinical and radiological findings were used most frequently (74.9%) as a diagnostic tool. While the most common treatment approaches were the use of systemic steroids and antifibrotic drugs with a rate of 30.7% and 85.6%, respectively. The total median cost from the patient-s admission to diagnosis was 540 Turkish Lira. Conclusion: We believe that our findings compared with data from other countries will be useful in showing the current situation of ILD in our country to discuss this problem and making plans for a solution.Publication Mesleki Enfeksiyon Hastalıkları(2019-08-01T00:00:00Z) Ogun, Hamza; Akkoyunlu, Yasemin; OGUN, HAMZA; AKKOYUNLU, YASEMİNPublication Covid-19 Hastalarının Tedavilere Uyumu(2022-03-19) Akkoyun M.; Ogun H.; Akkoyunlu Y.; OGUN, HAMZA; AKKOYUNLU, YASEMİNPublication Is short-course therapy enough at drug-resistant tuberculosis?(2018-01-01T00:00:00Z) OGUN, HAMZA; Ozmen, Ipek; Ozari Yildirim, Elif; Torun, Tulay; Calisir, Haluk Celalettin; OGUN, HAMZAIntroduction: Tuberculosis drug resistance can be assessed by physicians with different approaches on issues such as the choice of treatment protocol and duration of treatment.Publication The Effects of Polypharmacy, Nutritional and Functional Status on the Progression of COVID-19 in Older Adults(2021-08-01T00:00:00Z) Ogun, Hamza; Akkoyunlu, Yasemin; Durdu, Bülent; Okyaltırık, Fatmanur; Kazancıoğlu, Rümeyza; Meriç Koç, Meliha; Gülen, Bedia; Sümbül, Bilge; Okay, Gülay; Bolukcu, Sibel; Sönmez, Ertan; Kaçmaz, Asiye Bahar; Soysal, Pınar; Tan, Semen Gökçe; SOYSAL, PINAR; DURDU, BÜLENT; AKKOYUNLU, YASEMİN; OGUN, HAMZA; OKYALTIRIK, FATMANUR; OKAY, GÜLAY; SÜMBÜL, BİLGE; SÖNMEZ, ERTAN; MERİÇ KOÇ, MELİHA; KAZANCIOĞLU, RÜMEYZAPublication Thorax computed tomography findings and anti-SARS-CoV-2 immunoglobulin G levels in polymerase chain reaction-negative probable COVID-19 cases.(2022-11-25) Yurtsever I.; Karatoprak C.; Sumbul B.; Kiskac M.; Tunc M.; Zorlu M.; Ogun H.; Durdu B.; Toluk O.; Cakirca M.; YURTSEVER, İSMAİL; KARATOPRAK, CUMALİ; SÜMBÜL, BİLGE; KISKAÇ, MUHARREM; TUNÇ, MUHAMMED; ZORLU, MEHMET; OGUN, HAMZA; DURDU, BÜLENT; TOLUK, ÖZLEM; ÇAKIRCA, MUSTAFAOBJECTIVE: This study aimed to evaluate the SARS-CoV-2 immunoglobulin G (IgG) levels after 6 months of polymerase chain reaction (PCR) negativebut assumed to be COVID-19 positive cases to investigate the relationship between IgG levels and thoracic computed tomography (CT) findings.METHODS: This was a single-center study that included patients whose PCR test results were negative at least three times using nasopharyngealswabs but had clinical findings of COVID-19 and thoracic CT findings compatible with viral pneumonia. Six months after discharge, the IgG antibodieswere analyzed. The cutoff value for negative and positive serology was defined as <1.4 (index S/C) and ≥1.4 (index S/C), respectively. In addition, thepatients were categorized according to their thoracic CT findings as high (typical) and low (atypical). Also, the patients were grouped into classes as<5% lung involvement versus ≥5% lung involvement.RESULTS: The patients’ mean age was 49.78±12.96 years. PCR was negative, but patients with COVID-19 symptoms who had SARS-CoV-2 IgGpositive were 81.9% (n=95). The antibody titer and lung involvement ≥5% were statistically significantly higher in SARS-CoV-2 IgG positive cases(p<0.001 and p=0.021). Age and chest CT findings were the risk factors for lung involvement (OR=1.08, p<0.001 and OR=2.19, p=0.010, respectively).CONCLUSION: This study is valuable because increasing severity (≥5%) of lung involvement appears to be associated with high and persistent IgGantibody titers. In probable cases of COVID-19, even if the PCR test is negative, high IgG titers 6 months after discharge can predict the rate of lungparenchymal involvement.